_{*Full Eligibility Terms and Conditions: Direct purchase option is only available for KEPPRA XR® (levetiracetam) extended-release tablets prescriptions. Monthly pricing is based on patients taking 60 tablets of any branded KEPPRA XR tablets and pricing for a 3-month supply is based on patients taking 180 tablets. Patient must have a valid prescription consistent with the FDA-approved product labeling for KEPPRA XR to participate in the UCB Direct program for KEPPRA XR. The UCB Direct program for KEPPRA XR is available to residents of the United States and all United States Territories only. Program is not available where prohibited by law. The UCB Direct program for KEPPRA XR operates outside of any third-party insurance. Neither the patient nor the pharmacy nor anyone else acting on the patient’s behalf may submit any claim for reimbursement for product dispensed pursuant to this program to any third-party payer, including Medicare, Medicaid, or any other federal or state healthcare program. Out-of-pocket expenses incurred when using this program cannot be applied toward any government insurance benefit out-of-pocket spending calculations, such as Medicare Part D True Out-of-Pocket Costs (TrOOP). The UCB Direct program for KEPPRA XR does not include all Manufacturer products. Eligible patients may purchase the following Manufacturer products from the program: KEPPRA XR tablets. The UCB Direct program for KEPPRA XR is not health insurance. Limitations may apply. The UCB Direct program for KEPPRA XR cannot be combined with any other savings, free trial, or similar offer for the specified prescription. Manufacturer reserves the right to rescind, revoke, or amend this program without notice.}